cobicistat will raise the amount or impact of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
Acute enhancement or exacerbation of congestive coronary heart failure and new onset of decreased left ventricular ejection fraction have occurred
erythromycin ethylsuccinate will enhance the stage or outcome of bortezomib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
immediate stderr to outfile2 - it redirects it to what stdout was when the argument was encountered (outfile1) and then
bortezomib will improve the level or impact of clobazam by impacting hepatic enzyme CYP2C19 metabolism. Use Warning/Monitor. Dosage adjustment could possibly be necessary; CYP2C19 inhibitors may perhaps lead to improved exposure to N-desmethylclobazam (Energetic metabolite).
The therapeutic dose of bortezomib is individualized in Every single patient to avoid overdose. Lethal results occurred in people pursuing the administration of greater than two times the encouraged therapeutic dose of bortezomib. The signs and symptoms from overdose involved the acute onset of symptomatic hypotension and thrombocytopenia. AXL-IN-13 As there's no regarded antidote for bortezomib overdosage, checking of vital indications and appropriate supportive treatment ought to be initiated when drug overdosage is suspected.
bortezomib will improve the stage or outcome of tazemetostat by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
fosamprenavir will improve the stage or impact of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Nausea, diarrhea, constipation, and vomiting may have to Urolithin A have Bortezomib use of antiemetic and antidiarrheal prescription drugs or fluid replacement
Drug interactions may improve how your remedies get the job done or raise your chance for significant Negative effects. This doc won't incorporate all achievable drug interactions.
bosentan will minimize the extent or result of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Bortezomib is FDA-approved for use during the initial cure of numerous myeloma in combination with cyclophosphamide and dexamethasone. It is usually FDA-authorized for use during the therapy of many myeloma in people who previously responded to bortezomib and relapsed at the least 6 months once the completion of the prior treatment method.
rifapentine will lower the level or outcome of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
erythromycin stearate will improve the level or effect of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.